Luye Pharma Group Ltd.HKEX: 2186

Interim Report 2026

· Issued by Luye Pharma Group Ltd. via HKEXnews

Filed with HKEX · Stock code 2186 · · 69 pages · English

Summary by 6ix AI

The report highlights a decrease in revenue and gross profit compared to the previous year, while net profit and profit attributable to shareholders have increased. The company continues to focus on innovation in drug development, particularly in oncology and CNS therapeutic areas, with a robust pipeline of products. Luye Pharma operates globally, with a significant presence in major pharmaceutical markets and a commitment to expanding its research and development capabilities.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Luye Pharma Group Ltd. on 6ix

Earlier from Luye Pharma

Later from Luye Pharma

All Luye Pharma news releases